Seeking Alpha

Sanofi's (SNY) U300 "next-generation insulin" helped control the amount of sugar in the blood of...

Sanofi's (SNY) U300 "next-generation insulin" helped control the amount of sugar in the blood of diabetes patients in two Phase III trials, with fewer subjects suffering from dangerously low levels than with the company's blockbuster Lantus drug. The results of the testing are vital to Sanofi, as Lantus, which generated sales of €4.96B last year, is due to lose patent protection in 2015. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|